Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Following the creation of lecanemab, a dementia drug that can effectively slow memory loss for people in the earliest stages of Alzheimer’s disease, Alzheimer’s Research UK show how we at the ODDI can build on a network of research around the world to hopefully one day beat dementia.

It’s the breakthrough we’ve all been waiting for. A dementia drug called lecanemab can effectively slow memory loss for people in the earliest stages of Alzheimer’s disease.

But there is more good news to share. Lecanemab opens a door for many further breakthrough treatments – with drugs that will be more powerful, have fewer side effects and which can benefit millions more people, living with every kind of dementia.

You can help us to develop breakthrough new treatments to change the lives of who we love most.

Today, we are asking for you to support our Drug Discovery Alliance, which brings together world-leading dementia scientists from across the UK.

in their sights is a brand-new drug, designed to fix faults in brain cells that cause dementia, which could lead to a new life-changing treatment.

This work builds on decades of dedicated scientific research. But to get it across the finish line, we need you.

More information here.